Study participants were < 6 years old, had a diagnosis of CP, good functional abilities (Gross Motor Function Classification System level 1 or 2), equinovalgus (initial contact with the hallux or head of the first metatarsal) and overactive PL on EMG. The fore-, mid- and hindfoot were evaluated clinically and radiologically before and after injection of abobotulinumtoxinA (6–7 U/kg) into the PL. Radiological data were compared with reference values for children without pes planovalgus.
In total, 16 children (8 males; 10 hemiplegia, 6 diplegia; mean age: 3.2 ± 1.5 years) received treatment. Mean pre-and post-treatment angles in clinical assessment of dorsiflexion of the talocrural articulation did not differ with both knees flexed (24.4 ± 7.5 vs. 22.2 ± 8.0 degrees; P = 0.19) or extended (17.2 ± 8.0 vs. 16.6 ± 6.8 degrees; P = 0.36). Radiographic data pre-treatment versus reference data revealed forefoot pronation (metatarsal stacking angle 2.1 ± 8.3 vs. 8.0 ± 2.9 degrees; P = 0.002), midfoot planus (lateral talo-first metatarsal 28.5 ± 15.0 vs. 13.0 ± 7.5 degrees; P < 0.001; talocalcaneal angle 54.6 ± 8.6 vs. 49.0 ± 6.9 degrees; P = 0.004) and significantly decreased calcaneus dorsiflexion, without hindfoot equinus (calcaneal pitch angle 7.9 ± 6.0 vs. 17.0 ± 6.0 degrees; P < 0.001). After treatment, the metatarsal stacking angle did not differ from reference values (P = 0.15). As compared with before treatment, treatment improved mean angles for metatarsal stacking (2.1 ± 8.3 vs. 7.1 ± 3.9 degrees, respectively, P = 0.002), lateral talo-first metatarsal and talocalcaneal (both P < 0.001), with no change in the hindfoot.
PL may be an early target for abobotulinumtoxinA treatment in pes planovalgus associated with premature PL activity in children with CP.